ArticleMuscle & nerve2026
Optimization of the Cell-Based Assay Methodology to Study Degradation of Acetylcholine Receptors (Antigenic Modulation) by Antibodies From Myasthenia Gravis Patients.
Article in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
INTRODUCTION/
aimsDegradation of cell-surface acetylcholine receptors (AChRs) by antigenic modulation is a key pathogenic mechanism of myasthenia gravis (MG) autoantibodies, yet standard assays primarily detect antibody binding rather than functional effects. We therefore aimed to establish a standardized assay to evaluate the functional effects of MG autoantibodies on AChR modulation.
methodsCN21 cells expressing adult and fetal-type AChR were used to measure the modulation capacity of AChR antibodies in vitro. In this cell-based assay, the remaining surface AChR levels were determined using iodine-125-conjugated α-bungarotoxin. Experimental variables including plate surface and coating, cell density, dexamethasone treatment, incubation time, and complement effect were systematically evaluated and optimized. The optimized assay was later tested and qualified using sera from AChR-MG patients and healthy individuals.
resultsCellBIND coated 48-well plates were selected because of robust cell adhesion. An increased cell density resulted in increased baseline AChR expression levels without affecting the modulation capacity. Prolonged incubation of cells with AChR antibodies for 3 h resulted in higher sensitivity compared with 1 h. Heat inactivation of complement in serum samples did not affect antigenic modulation. DISCUSSION: The optimized modulation assay showed strong sensitivity and specificity, and is a robust and reproducible method to quantify modulation capacity in the sera of individual AChR-MG patients. We encourage the use of this assay to characterize the relevance of modulating antibodies in clinical severity and treatment response in individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.